Vemurafenib
This targeted therapy is used to treat melanoma that has spread to other parts of the body and carries a specific mutation in the BRAF gene (V600E). It works by blocking the mutated BRAF protein that tells cancer cells to grow uncontrollably. Resistance often develops within months of starting treatment, so it is sometimes combined with MEK inhibitors to prolong effectiveness.
Molekularmasse
489,9000 g/mol
LogP
5,00
TPSA
100,00 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Wirkmechanismus
Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.
2D-Struktur
Cite this structure
Embed this structure
SMILES
CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
InChI
InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)
Molecular Formula
C23H18ClF2N3O3S
HBD / HBA
2 / 7
Rotierbare Bindungen
7
Schwere Atome
33
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
This targeted therapy is used to treat melanoma that has spread to other parts of the body and carries a specific mutation in the BRAF gene (V600E). It works by blocking the mutated BRAF protein that tells cancer cells to grow uncontrollably. Resistance often develops within months of starting treatment, so it is sometimes combined with MEK inhibitors to prolong effectiveness.
Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.
Yes, Vemurafenib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1229517. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 42611257. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="vemurafenib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/vemurafenib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/vemurafenib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/vemurafenib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="vemurafenib"></drugfyi-drug>